AVEO Pharmaceuticals — Investor Presentation (July 2020)
26 slides from AVEO Pharmaceuticals's investor presentation, Jul 6, 2020
Slide 1: Pipeline Overview
Passionately pursuing a better life for patients with cancer July 2020 Pipeline Overview Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained
Slide 3: Pipeline: Multiple Potential Opportunities for Value Creation
Clinical Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib (RCC) VEGFR TKI Tivozanib (HCC) VEGFR TKI Ficlatuzumab Anti-HGF/c-MET mAb AV-203 (CAN017) Anti-ERBB3 mAb Multiple Potential Opportunities for Value Creation TIVO-1 (Phase 3 Registration Study in 1st Line RCC) T
Slide 4: Ficlatuzumab Anti-HGF/c-MET mAb
Ficlatuzumab Anti-HGF/c-MET mAb
Slide 5: Ficlatuzumab: A Potent anti-HGF/c-MET mAb
Ficlatuzumab: A Potent anti-HGF/c-MET mAb Hepatocyte growth factor (HGF) pathway is frequently dysregulated in a broad range of human cancers HGF can lead to both tumor growth and metastatic progression of cancer cells when dysregulated and is an escape mechanism to CT and targeted therapies, includ
Slide 6: Ficlatuzumab: Recently Completed and Ongoing Studies in Multiple Tumor Types
HNSCC: Randomized Phase 2 Trial Ongoing (Ficlatuzumab + Erbitux vs. Ficlatuzumab) Promising Phase 1 data - ASCO 2017 Topline Phase 2 data expected in 2021 AML: Randomized Phase 2 Trial On Hold Due to COVID-19 (Ficlatuzumab + Cytarabine vs. Ficlatuzumab) Promising Phase 1/2 data - AACR 2019 Pancreati
Slide 7: Ficlatuzumab: Head & Neck Cancer (HNSCC)
Ficlatuzumab: Head & Neck Cancer (HNSCC)
Slide 8: Ficlatuzumab: Rationale in HNSCC
Ficlatuzumab: Rationale in HNSCC HGF levels elevated in HNSCC tumor tissue ASCO 2017 Poster
Slide 9: Ficlatuzumab + Cetuximab: Phase 1 HNSCC Study Results in Cetuximab-Resistant Patients
Ficlatuzumab + Cetuximab: Phase 1 HNSCC Study Results in Cetuximab-Resistant Patients Combination was well tolerated with promising activity (ORR 17%, PFS 6mo, OS 8.2mo) ASCO 2017 Poster
Slide 10: Ficlatuzumab: Phase 2 Confirmatory Study Currently Enrolling Cetuximab-Resistant Patients
Ficlatuzumab: Phase 2 Confirmatory Study Currently Enrolling Cetuximab-Resistant Patients Due to CPI 1st line approvals study is recruiting 3rd line pts after CPI and Erbitux failures. Results expected 2021 * IRB Requiring Prior IO *
Slide 11: Ficlatuzumab: Acute Myeloid Leukemia (AML)
Ficlatuzumab: Acute Myeloid Leukemia (AML)
Slide 12: Ficlatuzumab: Rationale in AML
Ficlatuzumab: Rationale in AML ASCO Poster 2017
Slide 13: CyFi-1 Study: 50% CR Rate in Difficult to Treat AML Population
All enrolled patients experienced induction failure to 1st line treatment where 25-30% CR rate expected from chemo alone Ficlatuzumab CyFi-1 Study: 50% CR Rate in Difficult to Treat AML Population ASCO Poster 2017
Slide 14: Ficlatuzumab: Pancreatic Cancer
Ficlatuzumab: Pancreatic Cancer
Slide 15: Ficlatuzumab Pancreatic Cancer Phase 1/2 Results
Combination showed durable treatment responses Significant overlapping edema, study with alternate chemotherapy combo to be considered when new clinical supply is available ASCO GI Poster 2020
Slide 16: Ficlatuzumab: Immunotherapy Combination Opportunities Emerging
The c-Met-HGF axis promotes aberrant tumor cell growth, migration, proliferation, and angiogenesis Abnormal signaling results from c-Met over-expression, amplification or mutation of the c-Met receptor, or HGF over-expression C-Met expression is associated with expression of immunoregulatory protein
Slide 17: Ficlatuzumab Summary and Potential Milestones
Ficlatuzumab Summary Potential Ficlatuzumab (HGF MAb) Milestones 1H 20 2H 20 2021 HNSCC Randomized (Ficlatuzumab +/- ERBITUX®) Ph2 Confirmatory Data Pancreatic (Ficlatuzumab + Nab-paclitaxel + Gemcitabine) Ph1/2 Presentation AML CyFi-2 Randomized (DTIC +/- Ficlatuzumab) Ph2 Study Start HNSCC: Random
Slide 18: AV-380 Anti-GDF15 mAb
AV-380 M=O Anti-GDF15 mAb ONCOLOGY
Slide 19: Cancer Cachexia Impacts Patients Across a Broad Range of Tumor Types
Cancer Cachexia Impacts Patients Across a Broad Range of Tumor Types Cachexia is a complex metabolic syndrome associated with reduced food intake, muscle and adipose tissue loss, inflammation and anemia Approximately 50% of people with cancer will suffer from cachexia* Approximately 30% of all cance
Slide 20: Greater Than 70% of Cancer Patients Have Increased GDF15 Expression
Greater Than 70% of Cancer Patients Have Increased GDF15 Expression, Starting at the Pre-Cachectic Stage ** *** ** In collaboration with A Vigano % Patients Cancer Non-Cachexia Pre-cachexia Cachexia Refractory Cachexia GDF15 < 2.0 (ng/mL) 51% 29% 30% 21% GDF15 > 2.0 (ng/mL) 49% 71% 70% 79% GDF15 Dis
Slide 21: GDF15 Overexpression Causes Weight Loss; Inhibition Reverses Cachexia
Tumors Engineered to Overexpress GDF15 Cause Severe Weight Loss, Inhibition of GDF15 Reverses the Cachexia Phenotype Induced by Tumor Inhibition of GDF15 Reverses Cachexia in Animal Models 2mpk mIgG 2mpk anti-mGDF15 Ab Expression of GDF15 Induces Cachexia in Animal Models Lerner et al., (2016), J. o
Slide 22: GDF15 Has Been Shown to Predict Survival in Cancer Patients
GDF15 Has Been Shown to Predict Survival in Cancer Patients Survival analysis showed that GDF15 expression predicted survival adjusting for stage and weight change 1st quartile (low) 2nd quartile 3rd quartile 4th quartile (High) Percent Survival Days In collaboration with A. Vigano
Slide 23: Significant Market Opportunities Outside of Cancer
Increased GDF15 protein expression found in airway epithelium (mainly in ciliated cells) of human COPD smokers compared with normal non-smokers1 Cigarette smoke exposure consistently up-regulated GDF15 expression in human airway epithelial cells1 Significant Market Opportunities Outside of Cancer* A
Slide 24: AV-380 Development and Exclusivity Program
AV-380 Development and Exclusivity Program Development Status – Focused on Cancer Cachexia AV-380 is currently in preclinical development AVEO preparing IND for planned 2020 filing Intellectual Property Estate Method of use patent through 2029 to cover increasing body weight (e.g., treating cachexia
Slide 25: Key Potential Clinical and Regulatory Milestones
Key Potential Clinical and Regulatory Milestones AV-380 (Anti-GDF15 mAb) 1H 20 2H 20 2021 AV-380 IND Submission for Cancer Cachexia CAN017 (AV-203) (Anti-ERBB3 mAb) 1H 20 2H 20 2021 Initiate POC Study upon NRG1 Fusion Biomarker Evaluation Ficlatuzumab (Anti-HGF/c-MET mAb) 1H 20 2H 20 2021 HNSCC (Fic
Slide 26: Passionately pursuing a better life for patients with cancer
Passionately pursuing a better life for patients with cancer July 2020 Pipeline Overview
AVEO Pharmaceuticals — Investor Presentation (July 2020) on 6ix